Liothyronine use in primary hypothyroidism - current concepts.

Area of Science:

• Endocrinology
• Molecular Biology
• Clinical Medicine

Background:

• Hypothyroidism management presents clinical challenges, with standard levothyroxine (LT4) treatment failing to resolve symptoms in 5-10% of patients.
• Persistent symptoms despite normalized thyroid-stimulating hormone (TSH) levels negatively impact patient quality of life.
• Genetic variations, such as deiodinase 2 (D2) gene polymorphism, may influence treatment response.

Purpose of the Study:

• To explore the potential benefits of adding liothyronine (LT3) to levothyroxine (LT4) therapy for symptomatic hypothyroidism patients.
• To investigate the role of D2 gene polymorphism in predicting response to combination therapy.
• To highlight the need for evidence-based guidelines and biomarkers for personalized LT3/LT4 treatment.

Main Methods:

• Review of existing literature on hypothyroidism treatment with LT4 and potential adjunctive LT3 therapy.
• Discussion of D2 gene polymorphism and its implications for thyroid hormone metabolism.
• Analysis of recommended LT4/LT3 ratios and goals for combination therapy (physiological FT3/FT4 ratio, non-suppressed TSH).

Main Results:

• A subset of hypothyroid patients may remain symptomatic despite optimal TSH levels with LT4 monotherapy.
• Combination therapy with LT3 may offer symptomatic relief and improve quality of life in select individuals.
• Specific LT3 preparations and dosing ratios (e.g., 13:1-20:1 LT4/LT3) are considered.

Conclusions:

• Combination LT3/LT4 therapy is a potential option for carefully selected hypothyroid patients with persistent symptoms.
• Identifying biomarkers, potentially linked to D2 gene variations, is crucial for personalizing treatment strategies.
• Further clinical studies are required to establish evidence-based recommendations for LT3 use in primary hypothyroidism.